Investor Webinar: Nu.Q® NETs: Casting a New Light on Sepsis Management

Featuring Volition Chief Medical Officer, Dr. Andrew Retter, and Volition Chief Commercial Officer, Gael Forterre, the event focuses on Nu.Q^® NETs H3.1, a promising novel biomarker for early mortality and organ dysfunction in sepsis, and an independent predictor of the need for renal replacement therapy (RRT). The webinar also provides an update on Volition’s progress to commercialisation through both licensing and direct and indirect sales.

Recently published results from a large-scale study indicate a potential clinical utility for risk stratification and early intervention in critically ill patients presenting with sepsis.

Click here to access the replay.